Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy
| Autor: | Shi-Dou Lin, Shih-Te Tu, Shih-Li Su, Wayne Huey-Herng Sheu, Shih-Yi Lin, I-Te Lee, Yao-Hsien Tseng, Jun-Sing Wang, Wen-Jane Lee |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Randomization endocrine system diseases business.industry Endocrinology Diabetes and Metabolism nutritional and metabolic diseases 030209 endocrinology & metabolism Type 2 diabetes medicine.disease Gastroenterology Metformin Glibenclamide 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine Diabetes mellitus Ambulatory medicine 030212 general & internal medicine business Glycemic medicine.drug Acarbose |
| Zdroj: | Journal of Diabetes. 9:248-255 |
| ISSN: | 1753-0393 |
| Popis: | Background The aim of the present study was to examine the association between glycemic excursions before treatment and HbA1c reduction after treatment intensification with acarbose or glibenclamide in patients with type 2 diabetes (T2D). Methods Patients receiving single or dual oral antidiabetic drug treatment with an HbA1c of 7.0–11.0 % (53–97 mmol/mol) were switched to metformin monotherapy (500 mg, t.i.d.) for 8 weeks, followed by randomization to either acarbose (100 mg, t.i.d.) or glibenclamide (5 mg, t.i.d.) as add-on treatment for 16 weeks. Glycemic excursions were assessed as mean amplitude of glycemic excursions (MAGE) with 72-h ambulatory continuous glucose monitoring. Treatment efficacy was evaluated as relative HbA1c reduction (%), calculated as (baseline HbA1c – post-treatment HbA1c)/baseline HbA1c × 100. Results Fifty patients (mean [±SD] age 53.5 ± 8.2 years, 48 % men, mean baseline HbA1c 8.4 ± 1.2 %) were analyzed. Baseline MAGE was positively correlated with relative HbA1c reduction from baseline in patients treated with acarbose (r = 0.421, P = 0.029) but not glibenclamide (r = 0.052, P = 0.813). Linear regression analysis revealed that the association between baseline MAGE and relative HbA1c reduction from baseline (β = 0.125, P = 0.029) in patients treated with acarbose remained significant after adjustment for several confounders (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|